2 Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)

• Mate Nagy,
• Kristen Hurov,
• Johanna lahdenranta,
• Nicholas Keen,
• Dominic Smethurst,
• Qingyan Au,
• Heather Cohen,
• Carly Campbell,
• Stephen Blakemore,
• Tara Gelb,
• David Galbraith,
• Dan Rozelle,
• Erinn Parnell,
• Phil Brandish,
• Sebastien Hazard

Affiliations

Mate Nagy

1NeoGenomics, Aliso Viejo, CA, USA

Kristen Hurov

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Johanna lahdenranta

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Nicholas Keen

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Dominic Smethurst

clinical pharmacology physician

Qingyan Au

Neogenomics Laboratories, Fort Myers, Florida, USA

Heather Cohen

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Carly Campbell

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Stephen Blakemore

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Tara Gelb

1Bicycle Therapeutics, Lexington, MA, USA

David Galbraith

2Rancho Bio Sciences, San Diego, USA

Dan Rozelle

2Rancho Bio Sciences, San Diego, USA

Erinn Parnell

3NeoGenomics Laboratories, Aliso Viejo, USA

Phil Brandish

1Bicycle Therapeutics, Lexington, MA, USA

Sebastien Hazard

1Bicycle Therapeutics, Lexington, MA, USA